ArticleThe Journal of investigative dermatology2020
TERT, BRAF, and NRAS Mutational Heterogeneity between Paired Primary and Metastatic Melanoma Tumors.
Article in The Journal of investigative dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Genetic Concordance in Primary Cutaneous Melanoma and Matched Metastasis: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2023Pooled it
- Article
- Unmasking the "targetless" illusion: branched clonal evolution ofFrontiers in immunology · 2026Article
- Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Mutation analysis in individual circulating tumor cells depicts intratumor heterogeneity in melanoma.EMBO molecular medicine · 2024Article
- Article
- New Insights into Melanoma Tumor Syndromes.JID innovations : skin science from molecules to population health · 2022Review
- Associations between TERT Promoter Mutations and Survival in Superficial Spreading and Nodular Melanomas in a Large Prospective Patient Cohort.The Journal of investigative dermatology · 2022Article
- Genetic risk factors in melanoma etiopathogenesis and the role of genetic counseling: A concise review.Bosnian journal of basic medical sciences · 2022Review
- Skin Cancer Research Goes Digital: Looking for Biomarkers within the Droplets.Journal of personalized medicine · 2022Review
- Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR.Cancers · 2022Article
- Cell-Free DNA in Dermatology Research.The Journal of investigative dermatology · 2022Article
- Comparison of Two Rapid Assays for the Detection ofDiagnostics (Basel, Switzerland) · 2022Article
- BRAF Heterogeneity in Melanoma.Current treatment options in oncology · 2021Review
- Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma.International journal of molecular sciences · 2020Review
- Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA.Cancers · 2020Article
Corrections and comments
- Commented on by
Authors and funding
16 authors at 5 institutions in 2 countries.
Funding
Abstract
Mutational heterogeneity can contribute to therapeutic resistance in solid cancers. In melanoma, the frequencies of intertumoral and intratumoral heterogeneity are controversial. We examined mutational heterogeneity within individual patients with melanoma using multiplatform analysis of commonly mutated driver and nonpassenger genes. We analyzed paired primary and metastatic tumors from 60 patients and multiple metastatic tumors from 39 patients whose primary tumors were unavailable (n = 271 tumors). We used a combination of multiplex SNaPshot assays, Sanger sequencing, mutation-specific PCR, or droplet digital PCR to determine the presence of BRAF
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.